The European Commission has signed a contract for the supply of the vaccine to Pfizer



[ad_1]

The European Commission has signed an agreement to purchase 300 million doses of the vaccine from BioNTech and Pfizer. This came after the two drug companies announced that their experimental COVID-19 vaccine was 90% effective.

“As a company based in the heart of Europe, we expect to supply millions of people after approval from regulators,” BioNTech co-founder Ugur Shahin said in a statement.

CE to discuss Pfizer’s vaccine supply contract

The agreement with Pfizer and BioNTech was approved at today’s meeting of the European Commission and paves the way for the delivery of the vaccine in the EU member states.

“The European Commission has approved a fourth contract with the pharmaceutical companies BioNTech and Pfizer. It covers the purchase of 300 million doses as soon as the vaccine is approved to be safe and effective against COVID-19, ”said Eric Mamer.

The European Commissioner for Health explained that the preparation must be authorized by the European Medical Agency before it reaches community citizens.

The new coronavirus vaccine will also be available to the poorest countries. There, pharmaceutical companies will sell it cheaper than it costs to produce. News of its creation was greeted with relief in Europe.

ADVANCED IN THE BATTLE WITH COVID-19: The vaccine achieved 90% effectiveness

“We welcomed the news of the vaccine with joy. I hope everything is over soon. I have had three tests so far and I am currently waiting for my wife, who has been in contact with an infected person. We are fed up,” said Valentin Lafontaine.

Another pharmaceutical company, the American “Modern”, will announce at any time the data of the third stage of the clinical trials of its vaccine against COVID-19. The company plans to submit the emergency approval documents for the vaccine in early December.

Russia, meanwhile, said its vaccine had also shown 92% effectiveness against COVID-19. The team behind the Russian drug said it had analyzed data from 16,000 volunteers who had received two doses of the vaccine at 21-day intervals.

To be the first to know the news from Bulgaria and the world, download the new NOVA app – for Android HERE or iOS (Apple) HERE.



[ad_2]